News
FDA fast-tracks Leap’s gastric cancer immunotherapy
Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regula
